ALEMBICLTD

Alembic Share Price

₹100.57 -2.26 (-2.2%)

22 Feb, 2025 21:25

SIP TrendupStart SIP in ALEMBICLTD

Start SIP

Performance

  • Low
  • ₹99
  • High
  • ₹106
  • 52 Week Low
  • ₹78
  • 52 Week High
  • ₹169
  • Open Price₹103
  • Previous Close₹103
  • Volume443,727

Investment Returns

  • Over 1 Month -18.29%
  • Over 3 Month -18.41%
  • Over 6 Month -33.32%
  • Over 1 Year -2.5%
SIP Lightning

Smart Investing Starts Here Start SIP with Alembic for Steady Growth!

Invest Now

Alembic Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 8.2
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 2,583
  • P/B Ratio
  • 1.1
  • Average True Range
  • 5.66
  • EPS
  • 12.24
  • Dividend Yield
  • 2.4
  • MACD Signal
  • -5.75
  • RSI
  • 36.06
  • MFI
  • 32.57

Alembic Financials

Alembic Technicals

EMA & SMA

Current Price
₹100.57
-2.26 (-2.2%)
pointer
  • stock-down_img
  • Bearish Moving Average 15
  • stock-up_img
  • Bullish Moving Average 1
  • 20 Day
  • ₹107.57
  • 50 Day
  • ₹116.99
  • 100 Day
  • ₹123.28
  • 200 Day
  • ₹122.02

Resistance and Support

101.83 Pivot Speed
  • R3 110.59
  • R2 108.09
  • R1 104.33
  • S1 98.07
  • S2 95.57
  • S3 91.81

What's your outlook on Alembic?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Alembic Ltd. is a leading Indian pharmaceutical and healthcare company, specializing in the manufacturing of generic and branded formulations, active pharmaceutical ingredients (APIs), and bulk drugs. The company focuses on quality, innovation, and research to meet global healthcare needs.

Alembic (Nse) has an operating revenue of Rs. 210.65 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 65% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 50 which is a POOR score indicating inconsistency in earnings, a RS Rating of 39 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Alembic Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-07 Quarterly Results & Other To Consider other business matters. per share(30%)Final Dividend
2024-11-08 Quarterly Results & Other To Consider other business matters. per share(30%)Final Dividend
2024-08-12 Quarterly Results
2024-05-13 Audited Results & Final Dividend
2024-02-14 Quarterly Results
Date Purpose Remarks
2024-08-05 FINAL Rs.2.40 per share(120%)Final Dividend
2023-08-03 FINAL Rs.2.20 per share(110%)Final Dividend
2022-09-13 FINAL Rs.1.80 per share(90%)Dividend
View More

Alembic F&O

Alembic Shareholding Pattern

70.88%
1.78%
0.04%
21.75%
5.55%

About Alembic

  • NSE Symbol
  • ALEMBICLTD
  • BSE Symbol
  • 506235
  • Managing Director & CEO
  • Mrs. Malika Amin
  • ISIN
  • INE426A01027

Similar Stocks to Alembic

Alembic FAQs

Alembic share price is ₹100 As on 22 February, 2025 | 21:11

The Market Cap of Alembic is ₹2582.5 Cr As on 22 February, 2025 | 21:11

The P/E ratio of Alembic is 8.2 As on 22 February, 2025 | 21:11

The PB ratio of Alembic is 1.1 As on 22 February, 2025 | 21:11

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23